Citations (181)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Elijah Sanches, Marieke Timmermans, Besir Topal, Alper Celik, Magnus Sundbom, Rui Ribeiro, Chetan Parmar, Surendra Ugale, Monika Proczko, Pieter S. Stepaniak, Juan Pujol Rafols, Kamal Mahawar, Marc P. Buise, Aleksandr Neimark, Rich Severin & Sjaak Pouwels. (2019) Cardiac remodeling in obesity and after bariatric and metabolic surgery; is there a role for gastro-intestinal hormones?. Expert Review of Cardiovascular Therapy 17:11, pages 771-790.
Read now
Read now
Akiko Taira, Emiko Arita, Eriko Matsumoto, Ayano Oohira, Katsuro Iwase, Takaki Hiwasa, Koutaro Yokote, Shigenobu Shibata & Masaki Takiguchi. (2019) Systemic oscillator-driven and nutrient-responsive hormonal regulation of daily expression rhythms for gluconeogenic enzyme genes in the mouse liver. Chronobiology International 36:5, pages 591-615.
Read now
Read now
Xiao-Hui Guo. (2016) The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Current Medical Research and Opinion 32:1, pages 61-76.
Read now
Read now
Ellen E Ladenheim. (2015) Liraglutide and obesity: a review of the data so far. Drug Design, Development and Therapy 9, pages 1867-1875.
Read now
Read now
Giuseppina Opinto, Annalisa Natalicchio & Piero Marchetti. (2013) Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. Archives of Physiology and Biochemistry 119:4, pages 170-178.
Read now
Read now
Federica Tortosa & Francesco Dotta. (2013) Incretin hormones and beta-cell mass expansion: what we know and what is missing?. Archives of Physiology and Biochemistry 119:4, pages 161-169.
Read now
Read now
Joshua J Neumiller, Travis E Sonnett, Lindy D Wood, Stephen M Setter & R Keith Campbell. (2010) Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 3, pages 215-226.
Read now
Read now
Richard E. Pratley & Afshin Salsali. (2007) Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current Medical Research and Opinion 23:4, pages 919-931.
Read now
Read now
Tina Vilsbøll. (2007) Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus. Expert Opinion on Investigational Drugs 16:2, pages 231-237.
Read now
Read now
Jens Juul Holst. (2004) Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opinion on Emerging Drugs 9:1, pages 155-166.
Read now
Read now
. (2000) Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus. Expert Opinion on Therapeutic Patents 10:12, pages 1937-1942.
Read now
Read now
Articles from other publishers (170)
Michael A. Nauck, Matthias Blüher, Sebastian M. Meyhöfer, Elke Heitmann & Sven W Görgens. (2023) GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid. Diabetologie und Stoffwechsel 18:06, pages 475-487.
Crossref
Crossref
Mark M. Smits & Jens J. Holst. (2023) Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?. Diabetes/Metabolism Research and Reviews 39:8.
Crossref
Crossref
V. A. Genchi, G. Palma, G. P. Sorice, R. D’Oria, C. Caccioppoli, N. Marrano, G. Biondi, I. Caruso, A. Cignarelli, A. Natalicchio, L. Laviola, F. Giorgino & S. Perrini. (2023) Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?. Journal of Endocrinological Investigation.
Crossref
Crossref
Stine Smedegaard, Ulla Kampmann, Per G. Ovesen, Henrik Støvring & Nikolaj Rittig. (2023) Whey Protein Premeal Lowers Postprandial Glucose Concentrations in Adults Compared with Water—The Effect of Timing, Dose, and Metabolic Status: a Systematic Review and Meta-analysis. The American Journal of Clinical Nutrition.
Crossref
Crossref
Jerad H. Dumolt, Fredrick J. Rosario, Avery C. Kramer, Stacee Horwitz, Theresa L. Powell & Thomas Jansson. (2023) Maternal glucagon-like peptide-1 is positively associated with fetal growth in pregnancies complicated with obesity. Clinical Science 137:8, pages 663-678.
Crossref
Crossref
Jana Křenek Malíková, Irena Aldhoon Hainerová & Jan Lebl. (2023) Current pharmacotherapy options in pediatric obesity. Česko-slovenská pediatrie 78:2, pages 122-126.
Crossref
Crossref
Wathik Alsalim, Ola Lindgren & Bo Ahrén. (2022) Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation. Journal of Diabetes Investigation 14:3, pages 354-361.
Crossref
Crossref
Eui-Man Jung, Seung Hyun Lee & Geun-Shik Lee. (2023) Protective effects of Korean Red Ginseng against toxicity of endocrine-disrupting chemicals. Journal of Ginseng Research 47:2, pages 193-198.
Crossref
Crossref
Merlin C. Thomas, Melinda T. Coughlan & Mark E. Cooper. (2023) The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metabolism 35:2, pages 253-273.
Crossref
Crossref
Marieke TIMMERMANS, Besir TOPAL, Elijah E. SANCHES, Frank W. DE JONGH, Eylem CAGILTAY, Alper CELIK, Rui RIBEIRO, Chetan PARMAR, Surendra UGALE, Monika PROCZKO, Pieter S. STEPANIAK, Marc P. BUISE, Rich SEVERIN & Sjaak POUWELS. (2023) The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery. Minerva Endocrinology 47:4.
Crossref
Crossref
Casey Berman, Alaina P Vidmar & Lily C Chao. (2023) Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. European Endocrinology 19:1, pages 38.
Crossref
Crossref
Min chul Kim & Keun Sang Yum. (2022) The Efficacy of Using Liraglutide for Improving Non-Acoholic Fatty Liver Disease Condition in Pediatric-Adolescent Population with Obesity: Real World Evidence. Korean Journal of Family Practice 12:5, pages 361-366.
Crossref
Crossref
Bo Ahrén. (2022) Glucose‐dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice. Journal of Diabetes Investigation 13:10, pages 1655-1665.
Crossref
Crossref
Pamela Senesi, Anna Ferrulli, Livio Luzi & Ileana Terruzzi. (2022) Chrono-communication and cardiometabolic health: The intrinsic relationship and therapeutic nutritional promises. Frontiers in Endocrinology 13.
Crossref
Crossref
Anna Pii Hjørne, Ida Marie Modvig & Jens Juul Holst. (2022) The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion. Metabolites 12:5, pages 420.
Crossref
Crossref
Hashmat Ghanizada, Rune Häckert Christensen, Mohammad Al-Mahdi Al-Karagholi, Fatima Azzahra Elbahi, Hande Coskun & Messoud Ashina. (2022) Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study. Peptides 150, pages 170736.
Crossref
Crossref
Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim & Ji A Seo. (2022) GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Research and Clinical Practice 41:2, pages 136-149.
Crossref
Crossref
Qiming Tan, Seun E. Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller & Andrea M. Haqq. (2022) Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. Frontiers in Endocrinology 13.
Crossref
Crossref
Anita Kabahizi, Briana Wallace, Linh Lieu, Dominic Chau, Yanbin Dong, Eun‐Sang Hwang & Kevin W. Williams. (2021) Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics. British Journal of Pharmacology 179:4, pages 600-624.
Crossref
Crossref
Daniel I. Brierley & Guillaume de Lartigue. (2021) Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating. British Journal of Pharmacology 179:4, pages 584-599.
Crossref
Crossref
Guokun Yang, Xiaomin Liang, Chaobin Qin, Liping Yang, Yanmin Zhang, Ronghua Lu, Xiao Yan, Xiaolin Meng & Guoxing Nie. (2022) Molecular cloning, tissue distribution and functional characterization of glucose-dependent insulinotropic peptide (GIP) gene in Ctenopharyngodon idella. Aquaculture 548, pages 737682.
Crossref
Crossref
Charlotte Bayer Christiansen, Simon Veedfald, Bolette Hartmann, Astrid Marie Gauguin, Søren Møller, Thomas Moritz, Sten Madsbad & Jens Juul Holst. (2022) Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. The Journal of Clinical Endocrinology & Metabolism 107:1, pages 77-87.
Crossref
Crossref
Maria Ebbesen, Hannelouise Kissow, Bolette Hartmann, Katrine Kielsen, Kaspar Sørensen, Sara Elizabeth Stinson, Christine Frithioff-Bøjsøe, Cilius Esmann Fonvig, Jens-Christian Holm, Torben Hansen, Jens Juul Holst & Klaus Gottlob Müller. (2021) Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation. Frontiers in Immunology 12.
Crossref
Crossref
Feng Zhang, Zhinan Chen, Dan Wu, Le Tian, Qing Chen, Yuqing Ye, Wei Chen, Xiaoxing Wu, Peng Wu, Weilan Yuan, Yan Qiu, Zhiguang Zhou, Zhiqiang Du & Fang Hu. (2021) Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience 24:12, pages 103382.
Crossref
Crossref
Kimberly R. Smith & Timothy H. Moran. (2021) Gastrointestinal peptides in eating-related disorders. Physiology & Behavior 238, pages 113456.
Crossref
Crossref
Rune E. Kuhre, Carolyn F. Deacon, Jens J. Holst & Natalia Petersen. (2021) What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. Frontiers in Endocrinology 12.
Crossref
Crossref
Geremia B. Bolli, Francesca Porcellati, Paola Lucidi & Carmine G. Fanelli. (2021) The physiological basis of insulin therapy in people with diabetes mellitus. Diabetes Research and Clinical Practice 175, pages 108839.
Crossref
Crossref
Martha A. Schalla, Yvette Taché & Andreas Stengel. 2011. Comprehensive Physiology. Comprehensive Physiology
1679
1730
.
Tao Tao, Yi Zhang, Yu-Chen Zhu, Jia-Rong Fu, Yu-Ying Wang, Jie Cai, Jing-Yu Ma, Yu Xu, Yi-Ning Gao, Yun Sun, WuQiang Fan & Wei Liu. (2021) Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. The Journal of Clinical Endocrinology & Metabolism 106:3, pages e1420-e1432.
Crossref
Crossref
Jesper Vestlund & Elisabet Jerlhag. (2020) The glucagon-like peptide-1 receptor agonist, exendin-4, reduces sexual interaction behaviors in a brain site-specific manner in sexually naïve male mice. Hormones and Behavior 124, pages 104778.
Crossref
Crossref
Motoi Kobashi, Yuichi Shimatani, Masako Fujita, Yoshihiro Mitoh, Ryusuke Yoshida & Ryuji Matsuo. (2020) The Effects of Mutual Interaction of Orexin-A and Glucagon-Like Peptide-1 on Reflex Swallowing Induced by SLN Afferents in Rats. International Journal of Molecular Sciences 21:12, pages 4422.
Crossref
Crossref
Carolyn F Deacon. (2020) Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors. Peptides 125, pages 170196.
Crossref
Crossref
Momir Mikov, Nebojša Pavlović, Bojan Stanimirov, Maja Đanić, Svetlana Goločorbin-Kon, Karmen Stankov & Hani Al-Salami. (2019) DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. European Journal of Drug Metabolism and Pharmacokinetics 45:1, pages 1-14.
Crossref
Crossref
Emilie Balk-Møller, Johanne Agerlin Windeløv, Berit Svendsen, Jenna Hunt, Seyed Mojtaba Ghiasi, Charlotte Mehlin Sørensen, Jens Juul Holst & Hannelouise Kissow. (2020) Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease. Journal of the Endocrine Society 4:1.
Crossref
Crossref
Sara Lind Jepsen, Esben Thyssen Vestergaard, Pierre Larraufie, Fiona Mary Gribble, Frank Reimann, Jens Otto Lunde Jørgensen, Jens Juul Holst & Rune Ehrenreich Kuhre. (2020) Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1. The Journal of Clinical Endocrinology & Metabolism 105:1, pages 266-275.
Crossref
Crossref
T.D. Müller, B. Finan, S.R. Bloom, D. D'Alessio, D.J. Drucker, P.R. Flatt, A. Fritsche, F. Gribble, H.J. Grill, J.F. Habener, J.J. Holst, W. Langhans, J.J. Meier, M.A. Nauck, D. Perez-Tilve, A. Pocai, F. Reimann, D.A. Sandoval, T.W. Schwartz, R.J. Seeley, K. Stemmer, M. Tang-Christensen, S.C. Woods, R.D. DiMarchi & M.H. Tschöp. (2019) Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 30, pages 72-130.
Crossref
Crossref
Jens J. Holst, Nicolai J. Wewer Albrechtsen, Mette M. Rosenkilde & Carolyn F. Deacon. 2011. Comprehensive Physiology. Comprehensive Physiology
1339
1381
.
David S. Mathiesen, Jonatan I. Bagger, Natasha C. Bergmann, Asger Lund, Mikkel B. Christensen, Tina Vilsbøll & Filip K. Knop. (2019) The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review. International Journal of Molecular Sciences 20:17, pages 4092.
Crossref
Crossref
Hakan Dogruel & Mustafa Kemal Balci. (2019) Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future. World Journal of Diabetes 10:8, pages 446-453.
Crossref
Crossref
Maria Schou Ebbesen, Hannelouise Kissow, Bolette Hartmann, Kathrine Grell, Jette Sønderskov Gørløv, Katrine Kielsen, Jens Juul Holst & Klaus Müller. (2019) Glucagon-Like Peptide-1 Is a Marker of Systemic Inflammation in Patients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 25:6, pages 1085-1091.
Crossref
Crossref
Wei Zhu, Wen Huang, Zhiqiang Xu, Mengda Cao, Qiaoli Hu, Chen Pan, Miao Guo, Ji-Fu Wei & Hongyu Yuan. (2019) Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus. Frontiers in Pharmacology 10.
Crossref
Crossref
Rune V. Overgaard, Søren Ø. Lindberg & Desirée Thielke. (2019) Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. Diabetes, Obesity and Metabolism 21:1, pages 43-51.
Crossref
Crossref
Paola Simeone, Rossella Liani, Romina Tripaldi, Augusto Di Castelnuovo, Maria Guagnano, Armando Tartaro, Riccardo Bonadonna, Virginia Federico, Francesco Cipollone, Agostino Consoli & Francesca Santilli. (2018) Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients 10:12, pages 1872.
Crossref
Crossref
Christina C. Nexøe‐Larsen, Pernille H. Sørensen, Helene Hausner, Mikkel Agersnap, Mille Baekdal, Andreas Brønden, Lea N. Gustafsson, David P. Sonne, Louise Vedtofte, Tina Vilsbøll & Filip K. Knop. (2018) Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity. Diabetes, Obesity and Metabolism 20:11, pages 2557-2564.
Crossref
Crossref
Malin Nilsson, Albert Gjedde, Birgitte Brock, Michael Gejl & Jørgen Rungby. (2018) The effects of incretin hormones on cerebral glucose metabolism in health and disease. Neuropharmacology 136, pages 243-250.
Crossref
Crossref
Rasmus Hytting-Andreasen, Emilie Balk-Møller, Bolette Hartmann, Jens Pedersen, Johanne Agerlin Windeløv, Jens Juul Holst & Hannelouise Kissow. (2018) Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. PLOS ONE 13:6, pages e0198046.
Crossref
Crossref
Angelika Fretzen. (2018) Peptide therapeutics for the treatment of gastrointestinal disorders. Bioorganic & Medicinal Chemistry 26:10, pages 2863-2872.
Crossref
Crossref
Sheng Y Ang, Bronwyn A Evans, Daniel P Poole, Romke Bron, Jesse J DiCello, Ross A D Bathgate, Martina Kocan, Dana S Hutchinson & Roger J Summers. (2018) INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells. Journal of Molecular Endocrinology 60:3, pages 213-224.
Crossref
Crossref
David G King, Mark Walker, Matthew D Campbell, Leigh Breen, Emma J Stevenson & Daniel J West. (2018) A small dose of whey protein co-ingested with mixed-macronutrient breakfast and lunch meals improves postprandial glycemia and suppresses appetite in men with type 2 diabetes: a randomized controlled trial. The American Journal of Clinical Nutrition 107:4, pages 550-557.
Crossref
Crossref
Ji‐Hyun Lee, Xianlan Wen, Hana Cho & Seung‐Hoi Koo. (2018) CREB/CRTC2 controls GLP‐1‐dependent regulation of glucose homeostasis. The FASEB Journal 32:3, pages 1566-1578.
Crossref
Crossref
Mikkel B Christensen, Asger Lund, Salvatore Calanna, Niklas R Jørgensen, Jens J Holst, Tina Vilsbøll & Filip K Knop. (2018) Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. The Journal of Clinical Endocrinology & Metabolism 103:1, pages 288-294.
Crossref
Crossref
Motoi Kobashi, Satoshi Mizutani, Masako Fujita, Yoshihiro Mitoh, Yuichi Shimatani & Ryuji Matsuo. (2017) Central glucagon like peptide-1 inhibits reflex swallowing elicited by the superior laryngeal nerve via caudal brainstem in the rat. Brain Research 1671, pages 26-32.
Crossref
Crossref
F Samuel van Nierop, Matthijs J Scheltema, Hannah M Eggink, Thijs W Pols, David P Sonne, Filip K Knop & Maarten R Soeters. (2017) Clinical relevance of the bile acid receptor TGR5 in metabolism. The Lancet Diabetes & Endocrinology 5:3, pages 224-233.
Crossref
Crossref
Robert E. SteinertChristine Feinle-BissetLori AsarianMichael HorowitzChristoph BeglingerNori Geary. (2017) Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. Physiological Reviews 97:1, pages 411-463.
Crossref
Crossref
Shinya Kawamoto, Ryo Koda, Yuji Imanishi, Atsunori Yoshino & Tetsuro Takeda. (2016) The dipeptidyl peptidase-4 inhibitor may improve the insulin secretion in type 2 diabetes patients just after starting hemodialysis treatment: preliminary study. Renal Replacement Therapy 2:1.
Crossref
Crossref
Alexandra M. Bodnaruc, Denis Prud’homme, Rosanne Blanchet & Isabelle Giroux. (2016) Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutrition & Metabolism 13:1.
Crossref
Crossref
Yanwei Li, Lin Li & Christian Hölscher. (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences 27:7, pages 689-711.
Crossref
Crossref
Alison K. Gosby, Namson S. Lau, Charmaine S. Tam, Miguel A. Iglesias, Christopher D. Morrison, Ian D. Caterson, Jennie Brand-Miller, Arthur D. Conigrave, David Raubenheimer & Stephen J. Simpson. (2016) Raised FGF-21 and Triglycerides Accompany Increased Energy Intake Driven by Protein Leverage in Lean, Healthy Individuals: A Randomised Trial. PLOS ONE 11:8, pages e0161003.
Crossref
Crossref
L Liu, X Chu, L Na, F Yuan, Y Li & C Sun. (2016) Decreasing high postprandial stearic acid in impaired fasting glucose by dietary regulation. European Journal of Clinical Nutrition 70:7, pages 795-801.
Crossref
Crossref
Thea A.S. Halden, Erlend J. Egeland, Anders Åsberg, Anders Hartmann, Karsten Midtvedt, Hassan Z. Khiabani, Jens J. Holst, Filip K. Knop, Mads Hornum, Bo Feldt-Rasmussen & Trond Jenssen. (2016) GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. Diabetes Care 39:4, pages 617-624.
Crossref
Crossref
James Crane & Barbara McGowan. (2015) The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Therapeutic Advances in Chronic Disease 7:2, pages 92-107.
Crossref
Crossref
R E Steinert, C Beglinger & W Langhans. (2015) Intestinal GLP-1 and satiation: from man to rodents and back. International Journal of Obesity 40:2, pages 198-205.
Crossref
Crossref
M. A. de Laat, J. M. McGree & M. N. Sillence. (2016) Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation. American Journal of Physiology-Endocrinology and Metabolism 310:1, pages E61-E72.
Crossref
Crossref
Xiaoyan Zhou, Chin-hu Huang, Julie Lao, Alessandro Pocai, Gail Forrest, Olga Price, Sophie Roy, David E Kelley, Kathleen A Sullivan & Michael J Forrest. (2015) Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Jelena Kolic & Patrick E. MacDonald. (2015) cAMP-independent effects of GLP-1 on β cells. Journal of Clinical Investigation 125:12, pages 4327-4330.
Crossref
Crossref
Gunnar Sørensen, India A. Reddy, Pia Weikop, Devon L. Graham, Gregg D. Stanwood, Gitta Wortwein, Aurelio Galli & Anders Fink-Jensen. (2015) The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiology & Behavior 149, pages 262-268.
Crossref
Crossref
Louise W. Christensen, Rune E. Kuhre, Charlotte Janus, Berit Svendsen & Jens J. Holst. (2015) Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. Physiological Reports 3:9, pages e12551.
Crossref
Crossref
Astrid Plamboeck, Simon Veedfald, Carolyn F. Deacon, Bolette Hartmann, Tina VilsbøllFilip K. Knop & Jens J. Holst. (2015) The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 309:5, pages R544-R551.
Crossref
Crossref
Liyan Liu, Xinyang Wang, Ying Li & Changhao Sun. (2015) Postprandial Differences in the Amino Acid and Biogenic Amines Profiles of Impaired Fasting Glucose Individuals after Intake of Highland Barley. Nutrients 7:7, pages 5556-5571.
Crossref
Crossref
Yifei Zhang, Jie Chi, Weiqing Wang, Jie Hong, Weiqiong Gu, Bokai Wang & Guang Ning. (2015)
Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on
β
-cell function in a newly designed two-step hyperglycemic clamp 应用双重高糖钳夹新技术比较两种DPP-IV抑制剂与格列美脲对胰岛
β
细胞功能的不同影响
. Journal of Diabetes 7:2, pages 213-221.
Crossref
Crossref
Naomi J. McKay, Daniela L. Galante & Derek Daniels. (2014) Endogenous Glucagon-Like Peptide-1 Reduces Drinking Behavior and Is Differentially Engaged by Water and Food Intakes in Rats. The Journal of Neuroscience 34:49, pages 16417-16423.
Crossref
Crossref
Manuel Gil-Lozano, Erli L. Mingomataj, W. Kelly Wu, Sean A. Ridout & Patricia L. Brubaker. (2014) Circadian Secretion of the Intestinal Hormone GLP-1 by the Rodent L Cell. Diabetes 63:11, pages 3674-3685.
Crossref
Crossref
N. Nishii, S. Takashima, A. Iguchi, Y. Murahata, A. Matsuu, Y. Hikasa & H. Kitagawa. (2014) Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats. Domestic Animal Endocrinology 49, pages 14-19.
Crossref
Crossref
Kristian Karstoft, Kamilla Winding, Sine H. Knudsen, Noemi G. James, Maria M. Scheel, Jesper Olesen, Jens J. Holst, Bente K. Pedersen & Thomas P. J. Solomon. (2014) Mechanisms behind the superior effects of interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia 57:10, pages 2081-2093.
Crossref
Crossref
N A Rhee, S H Østoft, J J Holst, C F Deacon, T Vilsbøll & F K Knop. (2014) The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. European Journal of Endocrinology 171:3, pages 353-362.
Crossref
Crossref
Richard J. Davenport & Susanne Wright. (2014) Treating obesity: is it all in the gut?. Drug Discovery Today 19:7, pages 845-858.
Crossref
Crossref
Eng-Hong Pok. (2014) Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus. World Journal of Gastroenterology 20:39, pages 14315.
Crossref
Crossref
Danny Wadden, Farrell Cahill, Peyvand Amini, Edward Randell, Sudesh Vasdev, Yanqing Yi, Jon Church & Guang Sun. (2013) Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men. Nutrition & Metabolism 10:1.
Crossref
Crossref
N. J. McKay & D. Daniels. (2013) Glucagon-Like Peptide-1 Receptor Agonist Administration Suppresses Both Water and Saline Intake in Rats. Journal of Neuroendocrinology 25:10, pages 929-938.
Crossref
Crossref
Min Jung Kim, Hee Jin Son, Seo Hyeon Song, Myungji Jung, Yiseul Kim & Mee-Ra Rhyu. (2013) The TRPA1 Agonist, Methyl Syringate Suppresses Food Intake and Gastric Emptying. PLoS ONE 8:8, pages e71603.
Crossref
Crossref
C Benedict, J L Barclay, V Ott, H Oster & M Hallschmid. (2013) Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men. Nutrition & Diabetes 3:6, pages e78-e78.
Crossref
Crossref
Daniela Züger, Karoline Forster, Thomas A. Lutz & Thomas Riediger. (2013) Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli. Physiology & Behavior 112-113, pages 61-69.
Crossref
Crossref
M.R. Rekha & Chandra P. Sharma. (2013) Oral delivery of therapeutic protein/peptide for diabetes – Future perspectives. International Journal of Pharmaceutics 440:1, pages 48-62.
Crossref
Crossref
Mary Jane Geiger, Zachary Skrivanek, Brenda Gaydos, Jenny Chien, Scott Berry, Donald Berry & James H. AndersonJr.Jr.. (2012) An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics. Journal of Diabetes Science and Technology 6:6, pages 1319-1327.
Crossref
Crossref
Thomas Riediger. (2012) The receptive function of hypothalamic and brainstem centres to hormonal and nutrient signals affecting energy balance. Proceedings of the Nutrition Society 71:4, pages 463-477.
Crossref
Crossref
F. A. Duca & M. Covasa. (2012) Current and emerging concepts on the role of peripheral signals in the control of food intake and development of obesity. British Journal of Nutrition 108:5, pages 778-793.
Crossref
Crossref
Ehab Akkary. (2012) Bariatric Surgery Evolution from the Malabsorptive to the Hormonal Era. Obesity Surgery 22:5, pages 827-831.
Crossref
Crossref
Jens Juul Holst & Maria A. McGill. (2012) Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation 32:1, pages 1-14.
Crossref
Crossref
Christine M. Bruen, Fiona O'Halloran, Kevin D. Cashman & Linda Giblin. (2012) The effects of food components on hormonal signalling in gastrointestinal enteroendocrine cells. Food & Function 3:11, pages 1131.
Crossref
Crossref
Liza K. Phillips & Johannes B. Prins. (2011) Update on incretin hormones. Annals of the New York Academy of Sciences 1243:1, pages E55-E74.
Crossref
Crossref
Guillaume Carrel, Léonie Egli, Christel Tran, Philippe Schneiter, Vittorio Giusti, David D’Alessio & Luc Tappy. (2011) Contributions of fat and protein to the incretin effect of a mixed meal. The American Journal of Clinical Nutrition 94:4, pages 997-1003.
Crossref
Crossref
Yusuke Nakade, Toshinari Takamura, Masaru Sakurai, Hirofumi Misu, Mitsuko Nagata, Yuko Nanbu, Hiroyasu Oe, Toshiji Takamura, Yoshio Sakai, Shuichi Kaneko & Takashi Wada. (2011) Association between coefficients of variation of the R-R intervals on electrocardiograms and post-challenge hyperglycemia in patients with newly diagnosed type 2 diabetes. Journal of Diabetes Investigation 2:4, pages 324-327.
Crossref
Crossref
Y. Falkén, P. M. Hellström, J. J. Holst & E. Näslund. (2011) Changes in Glucose Homeostasis after Roux-en-Y Gastric Bypass Surgery for Obesity at Day Three, Two Months, and One Year after Surgery: Role of Gut Peptides. The Journal of Clinical Endocrinology & Metabolism 96:7, pages 2227-2235.
Crossref
Crossref
P. Barrington, J. Y. Chien, F. Tibaldi, H. D. H. Showalter, K. Schneck & B. Ellis. (2011) LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes, Obesity and Metabolism 13:5, pages 434-438.
Crossref
Crossref
Chrysi Koliaki & John Doupis. (2011) Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Therapy 2:2, pages 101-121.
Crossref
Crossref
Irfan VardarliMichael A. NauckLars D. KötheCarolyn F. DeaconJens J. HolstAnja SchweizerJames E. Foley. (2011) Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 96:4, pages 945-954.
Crossref
Crossref
M. J. Davies, R. Kela & K. Khunti. (2011) Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 13:3, pages 207-220.
Crossref
Crossref
S M Willbond & É Doucet. (2010) Individually timing high-protein preloads has no effect on daily energy intake, peptide YY and glucagon-like peptide-1. European Journal of Clinical Nutrition 65:1, pages 55-62.
Crossref
Crossref
Bernard Zinman. (2011) Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?. The American Journal of Medicine 124:1, pages S19-S34.
Crossref
Crossref
Michael A. Nauck. (2011) Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications. The American Journal of Medicine 124:1, pages S3-S18.
Crossref
Crossref
T. Edholm, M. Degerblad, P. Grybäck, L. Hilsted, J. J. Holst, H. Jacobsson, S. Efendic, P. T. Schmidt & P. M. Hellström. (2010) Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterology & Motility 22:11, pages 1191-e315.
Crossref
Crossref
Thomas M. Barber, Helen Begbie & Jonathan Levy. (2010) The incretin pathway as a new therapeutic target for obesity. Maturitas 67:3, pages 197-202.
Crossref
Crossref
Thomas Riediger, Nicole Eisele, Caroline Scheel & Thomas A. Lutz. (2010) Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 298:4, pages R1061-R1067.
Crossref
Crossref
Richard D. Carr, Marianne O. Larsen, Katarina Jelic, Ola Lindgren, Jenny Vikman, Jens J. Holst, Carolyn F. Deacon & Bo Ahrén. (2010) Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men. The Journal of Clinical Endocrinology & Metabolism 95:2, pages 872-878.
Crossref
Crossref
Bo Ahrén, Richard D. Carr & Carolyn F. Deacon. 2010. Incretins and Insulin Secretion. Incretins and Insulin Secretion
203
220
.
Brock E. Schroeder & Orville Kolterman. 2010. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
57
74
.
Arnab De & Richard D. DiMarchi. (2010) Synthesis and characterization of ester-based prodrugs of glucagon-like peptide 1. Biopolymers 94:4, pages 448-456.
Crossref
Crossref
Eduard Montanya & Giorgio Sesti. (2009) A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clinical Therapeutics 31:11, pages 2472-2488.
Crossref
Crossref
Marianne T. Neary & Rachel L. Batterham. (2009) Gut hormones: Implications for the treatment of obesity. Pharmacology & Therapeutics 124:1, pages 44-56.
Crossref
Crossref
Joshua J Neumiller & R Keith Campbell. (2009) Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy 43:9, pages 1433-1444.
Crossref
Crossref
Ola Lindgren, Andrea Mari, Carolyn F. Deacon, Richard D. Carr, Maria Sörhede Winzell, Jenny Vikman & Bo Ahrén. (2009)
Differential Islet and Incretin Hormone Responses in Morning
Versus
Afternoon after Standardized Meal in Healthy Men
. The Journal of Clinical Endocrinology & Metabolism 94:8, pages 2887-2892.
Crossref
Crossref
Kirsten Vollmer, Husai Gardiwal, Bjoern A. Menge, Oliver Goetze, Carolyn F. Deacon, Wolfgang E. Schmidt, Jens J. Holst & Juris J. Meier. (2009) Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans. The Journal of Clinical Endocrinology & Metabolism 94:4, pages 1379-1385.
Crossref
Crossref
Hyunsook Kim, Kim S. Stote, Kay M. Behall, Karen Spears, Bryan Vinyard & Joan M. Conway. (2009) Glucose and insulin responses to whole grain breakfasts varying in soluble fiber, β-glucan. European Journal of Nutrition 48:3, pages 170-175.
Crossref
Crossref
P. V. Højberg, T. Vilsbøll, R. Rabøl, F. K. Knop, M. Bache, T. Krarup, J. J. Holst & S. Madsbad. (2008) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:2, pages 199-207.
Crossref
Crossref
Jens Juul Holst. (2008) Pharmacology of GLP-1-based therapies. The British Journal of Diabetes & Vascular Disease 8:2_suppl, pages S10-S18.
Crossref
Crossref
Arnab De & Richard D. DiMarchi. (2008) Investigation of the Feasibily of an Amide-based Prodrug Under Physiological Conditions. International Journal of Peptide Research and Therapeutics 14:3, pages 255-262.
Crossref
Crossref
Jens J. Holst. (2008) The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 10, pages 14-21.
Crossref
Crossref
J.-F. Gautier, S.-P. Choukem & J. Girard. (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metabolism 34, pages S65-S72.
Crossref
Crossref
Harish Amin, Jens J. Holst, Bolette Hartmann, Laurie Wallace, Jim Wright & David L. Sigalet. (2008) Functional Ontogeny of the Proglucagon-Derived Peptide Axis in the Premature Human Neonate. Pediatrics 121:1, pages e180-e186.
Crossref
Crossref
Michael A. Nauck & Juris J. Meier. 2008. Pancreatic Beta Cell in Health and Disease. Pancreatic Beta Cell in Health and Disease
335
378
.
Wendell J. Lu, Qing Yang, William Sun, Stephen C. Woods, David D'Alessio & Patrick Tso. (2007) The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate. American Journal of Physiology-Gastrointestinal and Liver Physiology 293:5, pages G963-G971.
Crossref
Crossref
MA Elrishi, K Khunti, J Jarvis & MJ Davies. (2007) The dipeptidyl‐peptidase‐4 (DPP‐4) inhibitors: a new class of oral therapy for patients with type 2 diabetes mellitus. Practical Diabetes International 24:9, pages 474-482.
Crossref
Crossref
Jens Juul Holst. (2007) The Physiology of Glucagon-like Peptide 1. Physiological Reviews 87:4, pages 1409-1439.
Crossref
Crossref
M. Puig-Domingo & J. Reviriego. (2007) Las incretinas como nuevas dianas terapéuticas de la diabetes tipo 2. Revista Clínica Española 207:7, pages 352-364.
Crossref
Crossref
Laurie L. Baggio & Daniel J. Drucker. (2007) Biology of Incretins: GLP-1 and GIP. Gastroenterology 132:6, pages 2131-2157.
Crossref
Crossref
Tina VilsbøllFilip K Knop. (2016) Review: DPP IV inhibitors - current evidence and future directions. The British Journal of Diabetes & Vascular Disease 7:2, pages 69-74.
Crossref
Crossref
J. F. Todd & S. R. Bloom. (2007) Incretins and other peptides in the treatment of diabetes. Diabetic Medicine 24:3, pages 223-232.
Crossref
Crossref
Yukiomi Nakade, Kiyoshi Tsukamoto, Masahiro Iwa, Theodore N. Pappas & Toku Takahashi. (2007) Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats. Autonomic Neuroscience 131:1-2, pages 50-56.
Crossref
Crossref
Michael A. Nauck, Wolfgang E. Schmidt & Juris J. Meier. 2007. Pharmacotherapy of Diabetes: New Developments. Pharmacotherapy of Diabetes: New Developments
111
141
.
Gagik Radikovich Galstyan. (2006) Fiziologicheskaya rol' inkretinov:perspektivy lecheniya bol'nykhsakharnym diabetom 2 tipa. Diabetes mellitus 9:4, pages 14-18.
Crossref
Crossref
Wendy A. M. Blom, Anne Lluch, Sophie Vinoy, Annette Stafleu, Robin van den Berg, Jens J. Holst, Frans J. Kok & Henk F. J. Hendriks. (2006) Effects of gastric emptying on the postprandial ghrelin response. American Journal of Physiology-Endocrinology and Metabolism 290:2, pages E389-E395.
Crossref
Crossref
Rachel Fetner, James McGinty, Colleen Russell, F. Xavier Pi-Sunyer & Blandine Laferrère. (2005) Incretins, diabetes, and bariatric surgery: a review. Surgery for Obesity and Related Diseases 1:6, pages 589-597.
Crossref
Crossref
Krystyna Sztefko, Iwona Rogatko, Tomasz Milewicz, Józef Krzysiek, Przemyslaw J Tomasik & Zdzislaw Szafran. (2005) Effect of hormone therapy on the enteroinsular axis. Menopause 12:5, pages 630-638.
Crossref
Crossref
Frank A. Orlando, Carolina G. Goncalves, Zachariah M. George, John D. Halverson, Paul R. Cunningham & Michael M. Meguid. (2005) Neurohormonal pathways regulating food intake and changes after Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases 1:5, pages 486-495.
Crossref
Crossref
Philip J. Larsen & Jens Juul Holst. (2005) Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regulatory Peptides 128:2, pages 97-107.
Crossref
Crossref
Carolyn F. Deacon. (2005) What do we know about the secretion and degradation of incretin hormones?. Regulatory Peptides 128:2, pages 117-124.
Crossref
Crossref
JF Gautier, S Fetita, E Sobngwi & C Salaün-Martin. (2005) Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes & Metabolism 31:3, pages 233-242.
Crossref
Crossref
Howard Rosen & Thierry Abribat. (2005) The rise and rise of drug delivery. Nature Reviews Drug Discovery 4:5, pages 381-385.
Crossref
Crossref
Przemyslaw J. Tomasik, Krystyna Sztefko, Jerzy Starzyk, Iwona Rogatko & Zdzisław Szafran. (2005) Entero-insular axis in children with anorexia nervosa. Psychoneuroendocrinology 30:4, pages 364-372.
Crossref
Crossref
Rémy Burcelin. (2007) The incretins: a link between nutrients and well-being. British Journal of Nutrition 93:S1, pages S147-S156.
Crossref
Crossref
Mike Lee, Margono Hadi, Gunnel Halldén & Gregory W. Aponte. (2005) Peptide YY and Neuropeptide Y Induce Villin Expression, Reduce Adhesion, and Enhance Migration in Small Intestinal Cells through the Regulation of CD63, Matrix Metalloproteinase-3, and Cdc42 Activity. Journal of Biological Chemistry 280:1, pages 125-136.
Crossref
Crossref
Jens Juul Holst & Cathrine Ørskov. (2004) The Incretin Approach for Diabetes Treatment. Diabetes 53:suppl_3, pages S197-S204.
Crossref
Crossref
Mikael Nilsson, Marianne Stenberg, Anders H Frid, Jens J Holst & Inger ME Björck. (2004) Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. The American Journal of Clinical Nutrition 80:5, pages 1246-1253.
Crossref
Crossref
Bidda Rolin, Carolyn F Deacon, Richard D Carr & Bo Ahrén. (2004) The major glucagon-like peptide-1 metabolite, GLP-1-(9–36)-amide, does not affect glucose or insulin levels in mice. European Journal of Pharmacology 494:2-3, pages 283-288.
Crossref
Crossref
Michael A Nauck, Jörg Walberg, Arndt Vethacke, Andrea El-Ouaghlidi, Metin Senkal, Jens J Holst, J Baptist Gallwitz, Wolfgang E Schmidt & W Schmiegel. (2004) Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regulatory Peptides 118:1-2, pages 89-97.
Crossref
Crossref
Lene Hansen, Bolette Hartmann, Hitoshi Mineo & Jens J. Holst. (2004) Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regulatory Peptides 118:1-2, pages 11-18.
Crossref
Crossref
Juris J. Meier, Michael A. Nauck, Daniel Kranz, Jens J. Holst, Carolyn F. Deacon, Dirk Gaeckler, Wolfgang E. Schmidt & Baptist Gallwitz. (2004) Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. Diabetes 53:3, pages 654-662.
Crossref
Crossref
T. Vilsbøll & J. J. Holst. (2004) Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 47:3, pages 357-366.
Crossref
Crossref
Jens Juul Holst. 2004. Dipeptidyl Aminopeptidases in Health and Disease. Dipeptidyl Aminopeptidases in Health and Disease
263
279
.
Kristine Mortensen, Louise Lundby Christensen, Jens Juul Holst & Cathrine Orskov. (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regulatory Peptides 114:2-3, pages 189-196.
Crossref
Crossref
Tina Vilsbøll, Thure Krarup, Sten Madsbad & Jens J. Holst. (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides 114:2-3, pages 115-121.
Crossref
Crossref
Lise L. Kjems, Jens J. Holst, Aage Vølund & Sten Madsbad. (2003) The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion. Diabetes 52:2, pages 380-386.
Crossref
Crossref
Jens Juul Holst. (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1. Diabetes/Metabolism Research and Reviews 18:6, pages 430-441.
Crossref
Crossref
Bidda Rolin, Marianne O. Larsen, Carsten F. Gotfredsen, Carolyn F. Deacon, Richard D. Carr, Michael Wilken & Lotte Bjerre Knudsen. (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. American Journal of Physiology-Endocrinology and Metabolism 283:4, pages E745-E752.
Crossref
Crossref
Katri S Juntunen, Leo K Niskanen, Kirsi H Liukkonen, Kaisa S Poutanen, Jens J Holst & Hannu M Mykkänen. (2002) Postprandial glucose, insulin, and incretin responses to grain products in healthy subjects,,. The American Journal of Clinical Nutrition 75:2, pages 254-262.
Crossref
Crossref
Jens J. Holst. (2002) Gastric Inhibitory Polypeptide Analogues. BioDrugs 16:3, pages 175-181.
Crossref
Crossref
Crystal T. Peters, Yang-Ho Choi, Patricia L. Brubaker & G. Harvey Anderson. (2001) A Glucagon-Like Peptide-1 Receptor Agonist and an Antagonist Modify Macronutrient Selection by Rats. The Journal of Nutrition 131:8, pages 2164-2170.
Crossref
Crossref
A Flint, A Raben, AK Ersbøll, JJ Holst & A Astrup. (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity 25:6, pages 781-792.
Crossref
Crossref
E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, E. Pierazzuoli, S. Ciani, A. Fanelli, G. Messeri & C. M. Rotella. (2008) Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabetic Medicine 17:10, pages 713-719.
Crossref
Crossref
Hermann J. Kissler, Heike Gepp & Paul O. Schwille. (2000) METABOLIC CONSEQUENCES OF ORTHOTOPIC PANCREATICODUODENAL TRANSPLANTATION WITH PRESERVATION OF NEAR NORMAL PHYSIOLOGY1. Transplantation 70:5, pages 747-754.
Crossref
Crossref
Lene Hansen, Bolette Hartmann, Thue Bisgaard, Hitoshi Mineo, Peer N. Jørgensen & Jens J. Holst. (2000) Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology-Endocrinology and Metabolism 278:6, pages E1010-E1018.
Crossref
Crossref
Maddalena Peracchi, Alessandra Santangelo, Dario Conte, Mirella Fraquelli, Rosalia Tagliabue, Carlotta Gebbia & Marisa Porrini. (2007) The physical state of a meal affects hormone release and postprandial thermogenesis. British Journal of Nutrition 83:6, pages 623-628.
Crossref
Crossref
A Flint, A Raben, JF Rehfeld, JJ Holst & A Astrup. (2000) The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. International Journal of Obesity 24:3, pages 288-298.
Crossref
Crossref
Bolette Hartmann, Anders H Johnsen, Cathrine Ørskov, Kim Adelhorst, Lars Thim & Jens J Holst. (2000) Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 21:1, pages 73-80.
Crossref
Crossref
Erik Näslund, Jesper BogeforsStaffan SkogarPer Grybäck, Hans Jacobsson, Jens Juul Holst & Per M. Hellström. (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 277:3, pages R910-R916.
Crossref
Crossref
Jens Juul Holst. (1999) Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential. Trends in Endocrinology & Metabolism 10:6, pages 229-235.
Crossref
Crossref
H.J. Kissler, H. Gepp, A. Schmiedl & P.O. Schwille. (1999) Preservation of the incretin effect after orthotopic pancreas transplantation in inbred rats. Metabolism 48:5, pages 645-650.
Crossref
Crossref
André Wettergren, Morten Wøjdemann & Jens Juul Holst. (1998) Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. American Journal of Physiology-Gastrointestinal and Liver Physiology 275:5, pages G984-G992.
Crossref
Crossref
Andre Wettergren, Lone Pridal, Morten Wøjdemann & Jens Juul Holst. (1998) Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regulatory Peptides 77:1-3, pages 83-87.
Crossref
Crossref
A. Wettergren, M. Wøjdemann & J.J. Holst. (1998) The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide. Peptides 19:5, pages 877-882.
Crossref
Crossref